Trial Profile
Investigation of the Metabolism and Pharmacokinetics of 1200 μg (Free Cation) [14C] BEA 2180 BR Administered Orally Compared to 500 μg (Free Cation) [14C] BEA 2180 BR Administered Intravenously in Healthy Male Volunteers in an Open Label, Single-dose and Parallel Study Design
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Oct 2014
Price :
$35
*
At a glance
- Drugs BEA 2180-BR (Primary) ; BEA 2180-BR (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 10 Oct 2014 New trial record